Open Access

Treatment mechanism of matrine in combination with irinotecan for colon cancer

  • Authors:
    • Ling Duan
    • Leijiao Deng
    • Dabin Wang
    • Shoucheng Ma
    • Chunmei Li
    • Da Zhao
  • View Affiliations

  • Published online on: June 19, 2017     https://doi.org/10.3892/ol.2017.6407
  • Pages: 2300-2304
  • Copyright: © Duan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The inhibitory effect of matrine (MA) was studied in combination with irinotecan (CPT-11) on proliferation of human colon carcinoma cell line HT29. We also explored the mechanism of cell apoptosis induction in HT29. HT29 cells were treated with different concentrations of MA and CPT-11 alone and in combination. The growth inhibition in HT29 cells was evaluated using MTT assay. Apoptosis was detected using AV-PI double staining flow cytometry. Transmission electron microscopy was used to detect structural changes in cells. Topoisomerase (TOPO) I, Bax and Caspase-3 expression levels were evaluated using western blot analysis. MA and CPT-11 alone and in combination, inhibited the proliferation of HT29 cells, whereas the combination treatment exhibited higher inhibitory effect (P<0.01). This suggests the existence of synergistic cytotoxicity. Compared with each treatment alone, the combination treatment caused more significant damage to cell structure, and caused a significantly higher apoptosis rate (P<0.01). Additionally, the combination treatment increased TOPO I, Bax and Caspase-3 expression levels (P<0.01). In conclusion, MA in combination with CPT-11 synergistically inhibited HT29 cell proliferation and induced apoptosis in these cells. The mechanism may be related to upregulation of the TOPO I, Bax and Caspase-3 protein expression.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Duan L, Deng L, Wang D, Ma S, Li C and Zhao D: Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncol Lett 14: 2300-2304, 2017
APA
Duan, L., Deng, L., Wang, D., Ma, S., Li, C., & Zhao, D. (2017). Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncology Letters, 14, 2300-2304. https://doi.org/10.3892/ol.2017.6407
MLA
Duan, L., Deng, L., Wang, D., Ma, S., Li, C., Zhao, D."Treatment mechanism of matrine in combination with irinotecan for colon cancer". Oncology Letters 14.2 (2017): 2300-2304.
Chicago
Duan, L., Deng, L., Wang, D., Ma, S., Li, C., Zhao, D."Treatment mechanism of matrine in combination with irinotecan for colon cancer". Oncology Letters 14, no. 2 (2017): 2300-2304. https://doi.org/10.3892/ol.2017.6407